SCHEMBL5163474

SCHEMBL5163474

COc1cccc2c1c(O)c(C(=O)N(C)c1ccc(F)cc1F)c(=O)n2C

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.64
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
PGR P06401 1/20 0.43
MAPT P10636 2/20 0.40
RORC P51449 1/20 0.37
HIF1A Q16665 3/20 0.37
POLB P06746 2/20 0.37
ABCB1 P08183 2/20 0.37
ABCC1 P33527 2/20 0.37
TSHR P16473 1/20 0.37
TP53 P04637 1/20 0.36
THRB P10828 1/20 0.36
IMPDH2 P12268 1/20 0.36
BRPF1 P55201 4/20 0.35
PABPC1 P11940 1/20 0.35
BRD4 O60885 1/20 0.35
PIK3C3 Q8NEB9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5163897 0.92 HDAC4 (0.64) HDAC4MEN1KMT2APGRMAPT
SCHEMBL7001864 0.90 HDAC4 (0.66) HDAC4MEN1KMT2APGRMAPT
SCHEMBL7538308 0.87 HDAC4 (0.54) HDAC4MEN1KMT2AMAPTRORC
SCHEMBL1573840 0.87 HDAC4 (0.48) HDAC4MEN1KMT2APGRMAPT
SCHEMBL5165679 0.86 HDAC4 (0.47) HDAC4MEN1KMT2APGRMAPT
SCHEMBL7615940 0.85 HDAC4 (0.46) HDAC4MEN1KMT2APGRMAPT
SCHEMBL7722530 0.84 HDAC4 (0.46) HDAC4MEN1KMT2APGRMAPT
SCHEMBL7722529 0.84 HDAC4 (0.46) HDAC4MEN1KMT2APGRMAPT
SCHEMBL7617562 0.83 HDAC4 (0.45) HDAC4MEN1KMT2APGRMAPT
SCHEMBL7537746 0.82 HDAC4 (0.54) HDAC4MEN1KMT2AMAPTRORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1224172-B1 DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS ACTIVE BIOTECH AB (SE) 2007-04-04 EP claimed
US-6395750-B1 Includes laquinimod, N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxo-quinoline-3-carboxamide and its salts; breat or prostate cancer ACTIVE BIOTECH AB (SE) 2002-05-28 US claimed
EP-1224172-B1 DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS ACTIVE BIOTECH AB (SE) 2007-04-04 EP disclosed
EP-1095021-B1 QUINOLINE DERIVATIVES ACTIVE BIOTECH AB (SE) 2003-09-17 EP disclosed
US-6593343-B2 Quinoline derivatives ACTIVE BIOTECH AB (SE) 2003-07-15 US disclosed
US-20020173519-A1 Quinoline derivatives ACTIVE BIOTECH AB (SE) 2002-11-21 US disclosed
US-6395750-B1 Includes laquinimod, N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxo-quinoline-3-carboxamide and its salts; breat or prostate cancer ACTIVE BIOTECH AB (SE) 2002-05-28 US disclosed
US-6133285-A 1-METHYL-2-OXO-3-N-PHENYL-N-METHYLAMINOCARBONYL-4-HYDROXY-1,2 -DIHYDRO-QUINOLINES; AUTOIMMUNE DISEASE AND PATHOLOGICAL INFLAMMATION, E.G., ASTHMA, ATHEROSCLEROSIS, STROKE AND ALZHEIMER'S DISEASE AND, ESPECIALLY, MULTIPLE SCLEROSIS ACTIVE BIOTECH AB (SE) 2000-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173519-A1 Quinoline derivatives CASP1, NFKBIA, IL1B HDAC4 1771/4885MEN1 1499/4885KMT2A 3692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.